In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Immusol designs ribozymes for Pfizer targets

Executive Summary

Immusol has agreed to work with Pfizer indefinitely to validate new therapeutic targets in Pfizer's pipeline. Pfizer will first provide Immusol with gene target sequences so that it can design specific ribozymes to each target.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register